Toulouse, France

Armand Amselem


Average Co-Inventor Count = 1.2

ph-index = 4

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 1976-1983

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Armand Amselem: A Pioneer in Pharmaceutical Innovation

Introduction

Armand Amselem is a notable inventor based in Toulouse, France, recognized for his significant contributions to the pharmaceutical industry. With a total of 10 patents to his name, Amselem's work focuses on innovative compounds that have therapeutic applications, particularly related to blood platelet aggregation.

Latest Patents

Among his latest patents, Amselem has developed novel compounds, including the 5-o-Cyanobenzyl-4,5,6,7-tetrahydrothieno [3,2-c] pyridine acid addition salts. This invention highlights its inhibitory action against blood platelet aggregation without eliciting anti-inflammatory effects. In addition, he has also patented the free base form of this compound, which involves methods of preparation and therapeutic uses aimed at preventing blood platelet aggregation in warm-blooded animals.

Career Highlights

Amselem has built a notable career, having worked with prestigious companies such as Parcor and Centre d'Études Pour L'Industrie Pharmaceutique. His work at these organizations has facilitated significant advancements in pharmaceutical research, allowing him to explore and develop new therapeutic agents.

Collaborations

Throughout his career, Armand Amselem has collaborated with esteemed colleagues, including Fernand Eloy and Jean-Pierre Maffrand. These partnerships have contributed to his innovative research and the successful development of his patented inventions.

Conclusion

Armand Amselem’s contributions to the pharmaceutical industry through his innovative patents underscore his role as a key figure in pharmaceutical research. His work not only advances scientific understanding but also holds promise for future therapeutic applications, benefiting both the medical community and patients globally.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…